Larimar Therapeutics, Inc. (NASDAQ:LRMR) Financings

Larimar Therapeutics, Inc.

Financings

RaiseDate
Public offering of shares of common stock and pre-funded warrants
Announced: US$75M · J.P. Morgan +1
Dealers: J.P. Morgan (co-lead), Guggenheim Securities (co-lead)
Use of proceeds: Development of nomlabofusp, working capital and general corporate purposes, including R&D and commercialization expenses
Feb 25, 2026
Public offering of common stock
Closed: US$69M raised · US$3.2 a share · Leerink Partners +3
Dealers: Leerink Partners (co-lead), Guggenheim Securities (co-lead), Truist Securities (co-lead), William Blair (co-lead)
Use of proceeds: Development of nomlabofusp and other pipeline candidates, working capital and general corporate purposes including R&D and pre-commercialization
Jul 31, 2025

Read by 6ix AI from the company's releases